Cardiovascular Events, Acute Hospitalizations, and Mortality in Patients With Type 2 Diabetes Mellitus Who Initiate Empagliflozin Versus Liraglutide: A Comparative Effectiveness Study

Autor: Reimar W. Thomsen, Jakob S. Knudsen, Johnny Kahlert, Lisbeth M. Baggesen, Maria Lajer, Pia H. Holmgaard, Ola Vedin, Anastasia Ustyugova, Henrik T. Sørensen

Publikováno v: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 10, Iss 11 (2021)

Background In cardiovascular outcome trials, the sodium glucose cotransporter 2 inhibitor empagliflozin and glucagon‐like peptide‐1 (GLP‐1) receptor agonist liraglutide caused similar reductions in major adverse cardiac events (MACE). We compar

Externí odkaz: https://doaj.org/article/4eca55072e3d480ea3232432235fc9da

Healthcare Resource Utilization and Costs for Empagliflozin Versus Glucagon-Like Peptide-1 Receptor Agonists in Routine Clinical Care in Denmark

Autor: Reimar W. Thomsen, Lotte W. B. Christensen, Johnny Kahlert, Jakob S. Knudsen, Anastasia Ustyugova, Susanne Sandgaard, Pia Holmgaard, Lars H. Ehlers, Henrik T. Sørensen

Publikováno v: Thomsen, R W, Christensen, L W B, Kahlert, J, Knudsen, J S, Ustyugova, A, Sandgaard, S, Holmgaard, P, Ehlers, L H & Sørensen, H T 2022, ' Healthcare Resource Utilization and Costs for Empagliflozin Versus Glucagon-Like Peptide-1 Receptor Agonists in Routine Clinical Care in Denmark ', Diabetes therapy, vol. 13, no. 11-12, pp. 1891-1906 . https://doi.org/10.1007/s13300-022-01323-y

Introduction: The sodium-glucose cotransporter 2 inhibitor (SGLT2i) empagliflozin has shown reductions in major adverse cardiac events similar to glucagon-like peptide-1 receptor agonists (GLP-1RAs). However, evidence is limited about how these thera

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce24cff924555d44c2585fe56e250cdc
https://pubmed.ncbi.nlm.nih.gov/36315384

Changes in type 2 diabetes incidence and mortality associated with introduction of HbA1c as diagnostic option:A Danish 24-year population-based study

Autor: Jakob S. Knudsen, Signe S. Knudsen, Adam Hulman, Daniel R. Witte, Edward W. Gregg, Torsten Lauritzen, Lars Pedersen, Henrik T. Sørensen, Reimar W. Thomsen

Publikováno v: Knudsen, J S, Knudsen, S S, Hulman, A, Witte, D R, Gregg, E W, Lauritzen, T, Pedersen, L, Sørensen, H T & Thomsen, R W 2022, ' Changes in type 2 diabetes incidence and mortality associated with introduction of HbA1c as diagnostic option : A Danish 24-year population-based study ', The Lancet Regional Health-Europe, vol. 14, 100291 . https://doi.org/10.1016/j.lanepe.2021.100291
The Lancet Regional Health-Europe
The Lancet Regional Health. Europe, Vol 14, Iss, Pp 100291-(2022)

Background: In 2011, the World Health Organization began recommending glycated haemoglobin (HbA1c) as a measure for diagnosing type 2 diabetes (T2D). This initiative may have changed basic T2D epidemiology. Consequently, we examined time changes in T

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6fea978f02b05e06c1995f19cbf7d69c
https://pure.au.dk/portal/da/publications/changes-in-type-2-diabetes-incidence-and-mortality-associated-with-introduction-of-hba1c-as-diagnostic-option(bf8e21d1-90a6-4034-b42e-4ca29797cd65).html

A large remaining potential in lipid-lowering drug treatment in the type 2 diabetes population:A Danish nationwide cohort study

Autor: Bendix Carstensen, Maria Bekker-Nielsen Dunbar, Marit E. Jørgensen, Hanan Amadid, Pernille F. Rønn, Frederik Persson, Jakob S. Knudsen

Publikováno v: Amadid, H, Rønn, P F, Dunbar, M B N, Knudsen, J S, Carstensen, B, Persson, F & Jørgensen, M E 2021, ' A large remaining potential in lipid-lowering drug treatment in the type 2 diabetes population : A Danish nationwide cohort study ', Diabetes, Obesity and Metabolism, vol. 23, no. 10, pp. 2354-2363 . https://doi.org/10.1111/dom.14478
Amadid, H, Rønn, P F, Bekker-Nielsen Dunbar, M, Knudsen, J S, Carstensen, B, Persson, F & Jørgensen, M E 2021, ' A large remaining potential in lipid-lowering drug treatment in the type 2 diabetes population : A Danish nationwide cohort study ', Diabetes, Obesity and Metabolism, vol. 23, no. 10, pp. 2354-2363 . https://doi.org/10.1111/dom.14478

Aim: To assess lipid-lowering drug (LLD) use patterns during 1996-2017 and examine lipid levels in relation to the use of LLDs and prevalent atherosclerotic cardiovascular disease (ASCVD). Methods: Using a nationwide diabetes register, 404 389 indivi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d06fcc99af16dee334fb8393ebc27dd2
https://portal.findresearcher.sdu.dk/da/publications/019eb53d-fe82-4742-9687-5b5ecbde17ea

Hospitalization for hypoglycaemia in people with diabetes in Denmark, 1997-2017:Time trends in incidence and HbA1c and glucose-lowering drug use before and after hypoglycaemia

Autor: Reimar W. Thomsen, Mads Bengtsen, Maria Bisgaard Bengtsen, Jakob S. Knudsen, Niels Møller

Publikováno v: Bengtsen, M B, Knudsen, J S, Bengtsen, M B, Møller, N & Thomsen, RW 2021, ' Hospitalization for hypoglycaemia in people with diabetes in Denmark, 1997-2017 : Time trends in incidence and HbA1c and glucose-lowering drug use before and after hypoglycaemia ', Endocrinology, Diabetes & Metabolism, vol. 4, no. 3, e00227 . https://doi.org/10.1002/edm2.227
Endocrinology, Diabetes & Metabolism, Vol 4, Iss 3, Pp n/a-n/a (2021)
Endocrinology, Diabetes & Metabolism

Objective To assess incidence trends of first hospitalization for hypoglycaemia in Denmark and to examine HbA1c levels and glucose‐lowering drug use before and after hospitalization among individuals with type 1 or type 2 diabetes. Research Design

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f36746fa8e35ed927d52af832802f030
https://pure.au.dk/portal/da/publications/hospitalization-for-hypoglycaemia-in-people-with-diabetes-in-denmark-19972017(419abc6b-cfd1-4668-9045-6f0bae98557f).html